BKA
EBS icon

Brick & Kyle Associates’s Emergent Biosolutions EBS Stock Holding History

Brick & Kyle Associates’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-16
Closed – – 454
2014
Q4 		$0 Buy
+16
New +$381 ﹤0.01% 435

Other funds holding EBS

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
FMA
Fiduciary Management Associates Chicago, Illinois $1.53B AUM 4.47% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Brick & Kyle Associates's EBS Position: Q1 2015 in Review

Brick & Kyle Associates sold out of Emergent Biosolutions (EBS) in Q1 2015, closing a stake of 16 shares.

Brick & Kyle Associates first reported a position in EBS in Q4 2014 and held it in 1 quarter. The position peaked at $0 in Q4 2014. 172 funds tracked by Wall St. Rank hold EBS as of Q1 2015.

  • Brick & Kyle Associates reported no remaining Emergent Biosolutions position as of Q1 2015 after selling out during the quarter.
  • Brick & Kyle Associates sold 16 Emergent Biosolutions shares in Q1 2015.
  • Brick & Kyle Associates first reported a position in Emergent Biosolutions in Q4 2014 and held it in 1 quarter.
  • Brick & Kyle Associates's Emergent Biosolutions position peaked at $0 in Q4 2014.
  • 172 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2015.

Based on Brick & Kyle Associates's 13F filing for Q1 2015, filed 9 Apr 2015.